Phio Pharmaceuticals Corp.’s Post

Advancing a first-in-class AI-enabled cancer drug. A new article from Diana Spencer in Drug Discovery World looks at our REC-1245 program, a potentially first-in-class small molecule that recently received FDA IND clearance for a Phase 1/2 clinical trial for biomarker-enriched solid tumors and lymphoma. ▪ She writes: “Recursion identified the novel regulatory role of RBM39 associated with CDK12 using its maps of biology and first reported this relationship in early 2023, and notes that “preclinical data support that RBM39 degradation induces splicing defects which downregulate DNA Damage Response (DDR) networks and cell cycle checkpoints.” ▪ Chris Gibson says: “REC-1245 is a prime example of using an expansive AI-enabled platform for drug discovery. After exploring many predicted biological and chemical relationships across our maps of biology, we identified RMB39 as a novel target that looks functionally similar to the well-known but hard to drug target CDK12. We also identified and optimized small molecules that target RBM39 without directly impacting CDK12 or CDK13 using these same AI-enabled maps.” 👉 Read more: https://lnkd.in/ePy9XY5S #ai #clinicaltrials #techbio #cancer #tumor #cdk12 #rbm39

Our review on Peptides as innovative strategies to combat drug resistance in cancer therapy has been published in Drug Discovery today and is now available for reading. The review's three areas of focus for peptides to target drug resistant-cancer: Targeting tumour lipid membranes to kill proliferative & non-proliferative cells Peptide-drug conjugates to overcome drug efflux & improve tumour selectivity Cyclic peptides for targeting intracellular proteins in drug-resistant cancer Many thanks to my two amazing supervisors Sónia Troeira Henriques Henriques & Aurelie Benfield for their help and input along the way. Hopefully the beginning of more to come. Translational Research Institute Australia QUT (Queensland University of Technology)

US Antibody Drug Conjugates Market: Revolutionizing Cancer Treatment with Targeted Therapies Get Free PDF: https://lnkd.in/dHV3kCAJ The US Antibody Drug Conjugates (ADCs) market is witnessing a remarkable surge, valued at USD 1.3 Billion in 2023 and projected to reach USD 3.50 Billion by 2030, with a robust CAGR of 15.2%. ADCs represent a groundbreaking approach in cancer treatment, merging potent cell-killing small molecule drugs with monoclonal antibodies to precisely target tumor cells while sparing healthy tissue. #ADCs #CancerTreatment #Oncology #InnovativeTherapies #PrecisionMedicine #Healthcare #MedicalInnovation

In a study funded by our division, Meisam Bagheri, Ph.D., Todd Miller, PhD, Diwakar Pattabiraman, et al. found that eribulin (an FDA-approved chemotherapeutic drug) induces chromatin remodeling to reverse epithelial to mesenchymal transition and sensitizes cancer cells to other chemotherapies in preclinical models of triple-negative #BreastCancer. https://lnkd.in/erd5cpTu

🚀 Presenting ADC Digest for March 2024!🔬💊 This week, the realm of Antibody Drug Conjugates (ADCs) is buzzing with phenomenal breakthroughs! Here's a glimpse: 🌍 Samsung collaborates with BrickBio to pioneer cutting-edge molecules and therapies using protein engineering for ADCs 🌍 Antengene embarks on Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia, marking a significant stride in cancer treatment 🌍 Korean patients edge closer to affordable access to revolutionary cancer therapy, Enhertu. Stay tuned as we bring you more updates from the dynamic world of ADCs! #ADC #Antibodydrugconjugate #ADCnews #CIScientists #CompetitiveIntelligence #MedicalAdvancements #HealthcareRevolution Stay tuned for more updates in the world of ADCs!

Cell therapy is one of the greatest hopes for tackling the complexities of immuno-related diseases such as cancer. While promising, there is a lot of work to be done to make these treatments a reality for patients at large. Top three challenges in cell therapy research: 1. Precision insights – We need greater clarity in understanding cellular interactions and responses of how living drugs interact with the body. 2. Reliability - We need a greater understanding of complex factors that affect the efficacy of cell therapies across different patients and diseases through more robust and reproducible measurements. 3. Cost - We need to reduce the cost of cell therapy, which can be>$1M, making it inaccessible to many patients by lowering both R&D and manufacturing costs. Image: Cancer cell therapy landscape by therapy type and year. Nature Reviews Drug Discovery 21, 631-632 (2022) #pharma #immunotherapy #celltherapy

Cell therapy is one of the greatest hopes for tackling the complexities of immuno-related diseases such as cancer. While promising, there is a lot of work to be done to make these treatments a reality for patients at large. Top three challenges in cell therapy research: 1. Precision insights – We need greater clarity in understanding cellular interactions and responses of how living drugs interact with the body. 2. Reliability - We need a greater understanding of complex factors that affect the efficacy of cell therapies across different patients and diseases through more robust and reproducible measurements. 3. Cost - We need to reduce the cost of cell therapy, which can be>$1M, making it inaccessible to many patients by lowering both R&D and manufacturing costs. Image: Cancer cell therapy landscape by therapy type and year. Nature Reviews Drug Discovery 21, 631-632 (2022) #pharma #immunotherapy #celltherapy

The Advantages of Using Primary Derived Cancer Cell Lines in Drug Discovery IN THE RAPIDLY EVOLVING FIELD OF DRUG DISCOVERY, CHOOSING THE RIGHT CELL MODEL IS CRUCIAL FOR DEVELOPING EFFECTIVE CANCER TREATMENTS. TRADITIONALLY, ESTABLISHED CANCER CELL LINES HAVE BEEN WIDELY USED DUE TO THEIR EASE OF CULTURE AND AVAILABILITY. Enhanced Relevance: They better mimic the tumor's original characteristics, providing more accurate insights. Improved Predictability: These cell lines reflect patient-specific responses, leading to more reliable drug efficacy predictions. Diverse Genetic Profiles: They capture the genetic diversity of cancer, aiding in the development of targeted therapies. https://lnkd.in/g7MczWS5 #DrugDiscovery #CancerResearch #PrimaryCancerCellLines #InnovativeTherapies #ResearchAdvancements #Biotech #CancerTreatment

Chimeric Antigen Receptor (CAR) T Cell Therapy offers a innovative approach in immunotherapy harnessing immune cells to target and eliminate target cells such as cancer cells.  But what critical steps ensure development of safe and efficacious therapies? The journey from discovery to clinical application begins with three critical steps: target identification, CAR design, and preclinical testing. Each stage plays a crucial role in developing safe and effective therapies. Whether you're involved in research, development, or clinical applications, understanding these early stages is crucial for success. We break down the first stages of CAR T cell therapy development, answering essential questions such as: - What are the critical steps in the development of CAR T cell therapy? - How is a target antigen selected for CAR T cell therapy, and why is it important? - What are the components of a Chimeric Antigen Receptor (CAR), and how do they function? - What methods are used to test the safety and efficacy of CAR T cells in preclinical development? - Why is preclinical testing essential before moving CAR T therapies into clinical trials? Are you curious to learn more about CAR T cell therapy?  Read the full blog here: https://lnkd.in/gspRwetf #immunotherapy #cartcelltherapy #biotech #oncology #research #celltherapy

T cell leukemias and lymphomas originate from the clonal expansion of a specific T cell, resulting in every cancerous T cell having the same TCR sequence. Anti-TRBC1 CAR-T cell therapy, though attempted, has failed in clinical trials due to poor expansion. Researchers from Dr. Suman Paul's lab at The Johns Hopkins University School of Medicine focused on developing an antibody therapeutic targeting TRBC1+ cells, independent of CAR-T cells. They created antibody-drug conjugates (ADCs) against TRBC1, demonstrating potency and efficacy through both in vivo and in vitro experiments. Additionally, they performed drug-antibody-ratio (DAR) analysis using Rapid Novor's LC-MS antibody characterization service. This step is crucial for ADC development, ensuring optimal drug delivery to cancer cells while minimizing off-target effects and toxicity. Read the case study here: https://hubs.li/Q02FPMWm0 #ADCs #AntibodyDrugConjugates #AntibodyTherapeutics #Therapeutics #AntibodyCharacterization